Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Odonate's Oral Taxane Tesetaxel Shows PFS Benefit In Metastatic Breast Cancer Phase III

Executive Summary

The convenient oral therapy could have benefits over more traditional infused taxane chemotherapies, and a new drug application filing is planned for 2021.

You may also be interested in...



Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease

Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.

High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict

Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.

Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication

Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel